Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01659307 | The Effect of Aspirin on REducing iNflammation in Human in Vivo Model of Acute Lung Injury | PHASE2 | COMPLETED | 33 | — | — | Sep 1, 2012 | Sep 9, 2022 | Sep 13, 2022 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Aspirin 75mg | ACTIVE_COMPARATOR | Aspirin 75mg once daily for 7 days. Administered by mouth. |
| Aspirin 1200mg | ACTIVE_COMPARATOR | Asprin 600mg twice daily for 7 days. Administered by mouth. |
| Lactose powder | PLACEBO_COMPARATOR | Placebo for 7 days. Administered by mouth. |
| Name | Type | Description |
|---|---|---|
| Aspirin 75mg | DRUG | Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening. |
| Lactose powder | DRUG | Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening. |
| Aspirin 1200mg | DRUG | Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening. |
Inclusion Criteria: * Healthy subjects Exclusion Criteria: * Age \< 18 years * Pregnancy or breast feeding or woman of childbearing potential not using * adequate contraception. * Participation in a clinical trial of an investigational medicinal product within 30 days * Consent declined Aspirin o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Fresenius Medical Care AG Sponsored ADR | FMS | 2 | PHASE3 | Dialysis |
| AstraZeneca PLC | AZN | 1 | PHASE2 | AZD4144 |
| CalciMedica, Inc. | CALC | 1 | PHASE2 | Auxora |
| Talphera, Inc. | TLPH | 1 | NA | Undisclosed |
| SeaStar Medical Holding Corporation | ICU | 2 | — | Undisclosed |
| Collegium Pharmaceutical, Inc. | COLL | 1 | — | Flozin |